Completely unique and synthetic, GEM 21S® is an innovative combination of a bioactive protein (highly purified recombinant human platelet derived growth factor, rhPDGF-BB) and a biocompatible osteoconductive matrix (beta-tricalcium phosphate, β-TCP)
GEM 21S® contains 1000x more active growth factor (PDGF) than found in platelet rich plasma.1-4
Compared to bone graft substitute without PDGF5:
Provides 3x more bone fill at 6 months
Provides a more predictable treatment option even in the most severe casesFor Unprecedented Results
Where bone augmentation is warranted, GEM 21S® is clinically proven to significanlty:
Improve bone growth resulting in increased bone fill Accelerate clinical attachment level gains Reduce Gingival recessionView the Package Insert:
United States Canada - English Canada - FrenchTo view a presentation about GEM 21S®, click here.
GEM 21S® has been approved for use in the United States and
Canada for the treatment of:
Intrabony periodontal defects Furcation periodontal defects Gingival recession associated with periodontal defects.
GEM 21S® is a registered trademark of BioMimetic Therapeutics, Inc. and is marketed under license by Osteohealth, a Division of Luitpold Pharmaceuticals, Inc.
Osteohealth Company | Contact Us | © 2006 Luitpold Pharmaceuticals, Inc. Company | Privacy Policy | Terms of Use